- My Account, Sign out Sign in / Register
- |
- Live Chat
- |
-
English
FGF8 Antibody
Rabbit Polyclonal
Catalog number: 20711-1-AP



Ask a question about this product click here
Loading price...
Applications
| Tested applications | ELISA, WB, IHC |
| Cited applications | |
| Species specificity | human, mouse, rat; other species not tested. |
| Cited species | |
| Positive WB detected in | HeLa cells, L02 cells |
| Positive IHC detected in | human breast cancer |
| Recommended dilution | WB: 1:200-1:2000 IHC: 1:20-1:200 |
Application key: WB = Western blotting, IHC = Immunohistochemistry, IF = Immunofluorescence,
IP = Immunoprecipitation
IP = Immunoprecipitation
Images
HeLa cells were subjected to SDS PAGE followed by western blot with 20711-1-AP(FGF8 Antibody) at dilution of 1:600
Immunohistochemistry of paraffin-embedded human breast cancer using 20711-1-AP(FGF8 Antibody) at Dilution 1:50 (under 10x lens)
Immunohistochemistry of paraffin-embedded human breast cancer using 20711-1-AP(FGF8 Antibody) at Dilution 1:50 (under 40x lens)
Product Information
| Source | Rabbit | Purification method | Antigen affinity purification |
| Isotype | IgG | Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Store at -20oC. |
Immunogen Information
| Immunogen | Peptide | Full name | fibroblast growth factor 8 (androgen-induced) |
|
Calculated molecular weight |
27kd |
Observed molecular
weight |
23kd |
|
GenBank accession number |
NM_006119 | Gene ID (NCBI) | 2253 |
| Gene symbol | FGF8 | Synonyms | AIGF; HBGF-8; KAL6; MGC149376 |
Background
FGF8, also named as AIGF and HBGF-8, belongs to the heparin-binding growth factors family. FGF8 stimulates growth of the cells in an autocrine manner. It mediates hormonal action on the growth of cancer cells. Defects in FGF8 are the cause of Kallmann syndrome type 6 (KAL6). Defects in FGF8 are a cause of idiopathic hypogonadotropic hypogonadism (IHH). The antibody is specific to FGF8. |
Related Primary Antibodies:
Related Fusion Proteins:
Related Secondary Antibodies:
Loading...

